Ionis Pharmaceuticals (FRA:ISI) FFO


FRA:ISI Ionis Pharmaceuticals Inc FRA:ISI
65 GF Score
Price €71.72
GF Value €47.81
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

FRA:ISI
65GF Score
Ionis Pharmaceuticals Inc FRA:ISI
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ionis Pharmaceuticals (FRA:ISI) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of €71.72 is trading 50% above its estimated GF Value™ of €47.81. GuruFocus considers Ionis Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:ISI:

  • FFO:
  • GF Value™: €47.81 vs. price of €71.72 (50% above fair value)
  • GF Score™: 65/100 with 8 warning signs

No single metric tells the full story. See the FRA:ISI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ionis Pharmaceuticals Business Description

Other Exchanges IONS:USA1IONS:Italy0JDI:UK
Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
65GF Score

Get the complete analysis for FRA:ISI

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€71.72
Price
€47.81
GF Value